UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

American journal of transplantation, 2012-09, Vol.12 (9), p.2446-2456

2012

Volltextzugriff (PDF)

Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients

American journal of transplantation, 2009-08, Vol.9 (8), p.1936-1945

2009

Volltextzugriff (PDF)

Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients

American journal of transplantation, 2015-06, Vol.15 (6), p.1644-1653

2015

Volltextzugriff (PDF)

Calcineurin‐Inhibitor‐Free Immunosuppression Based on the JAK Inhibitor CP‐690,550: A Pilot Study in De Novo Kidney Allograft Recipients

American journal of transplantation, 2009-08, Vol.9 (8), p.1936-1945

2009

Volltextzugriff (PDF)

P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i914-i916

2023

Volltextzugriff (PDF)

DOP59 Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscore

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S094-S095

2021

Volltextzugriff (PDF)

P260 An analysis of non-melanoma skin cancer rates in the tofacitinib Ulcerative Colitis clinical programme

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S294-S296

2021

Volltextzugriff (PDF)

OP38 Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i044-i045

2022

Volltextzugriff (PDF)

P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i446-i447

2022

Volltextzugriff (PDF)

P607 Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i538-i539

2022

Volltextzugriff (PDF)

P378 Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE Open

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i380-i381

2022

Volltextzugriff (PDF)

Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe

International journal of clinical pharmacology and therapeutics, 2009-02, Vol.47 (2), p.111

2009

Volltextzugriff (PDF)

P334 Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programme

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S357-S359

2021

Volltextzugriff (PDF)

DOP85 Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S116-S117

2021

Volltextzugriff (PDF)

P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S460-S461

2020

Volltextzugriff (PDF)

DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S098-S099

2020

Volltextzugriff (PDF)

P409 Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S416-S417

2021

Volltextzugriff (PDF)

P336 Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S361-S362

2021

Volltextzugriff (PDF)

DOP61 Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S096-S097

2021

Volltextzugriff (PDF)

P342 Diagnostic accuracy of rectal bleeding and stool frequency in predicting mucosal healing in patients with ulcerative colitis in the tofacitinib OCTAVE Phase 3 induction studies

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S328-S329

2020

Volltextzugriff (PDF)

P531 Efficacy of tofacitinib maintenance therapy for ulcerative colitis in remitting patients vs. patients with clinical response after 8 weeks of induction treatment

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S378-S379

2019

Volltextzugriff (PDF)

DOP75 Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S112-S113

2020

Volltextzugriff (PDF)

DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S100-S101

2020

Volltextzugriff (PDF)

P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S557-S558

2020

Volltextzugriff (PDF)

P653 Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Updated results of the OCTAVE Open study for tofacitinib 8-week induction non-responders

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S537-S539

2020

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(5)
Male
(5)
Science & Technology
(5)
Surgery
(5)
Adult
(4)
Female
(4)
Humans
(4)
Middle Aged
(4)
Transplantation
(4)
Biological And Medical Sciences
(3)
Immunosuppressive Agents - Adverse Effects
(3)
Immunosuppressive Agents - Therapeutic Use
(3)
Kidney
(3)
Medical Sciences
(3)
Pyrimidines - Adverse Effects
(3)
Pyrimidines - Therapeutic Use
(3)
Pyrroles - Adverse Effects
(3)
Pyrroles - Therapeutic Use
(3)
Biopsy
(2)
Dose-Response Relationship, Drug
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients

Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients

Calcineurin‐Inhibitor‐Free Immunosuppression Based on the JAK Inhibitor CP‐690,550: A Pilot Study in De Novo Kidney Allograft Recipients

P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING study

DOP59 Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscore

P260 An analysis of non-melanoma skin cancer rates in the tofacitinib Ulcerative Colitis clinical programme

OP38 Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials

P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open

P607 Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open

P378 Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE Open

Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe

P334 Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programme

DOP85 Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study

P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme

DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open

P409 Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study

DOP61 Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study

P342 Diagnostic accuracy of rectal bleeding and stool frequency in predicting mucosal healing in patients with ulcerative colitis in the tofacitinib OCTAVE Phase 3 induction studies

P531 Efficacy of tofacitinib maintenance therapy for ulcerative colitis in remitting patients vs. patients with clinical response after 8 weeks of induction treatment

DOP75 Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study

DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment

P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme

P653 Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Updated results of the OCTAVE Open study for tofacitinib 8-week induction non-responders

Suchergebnisse filtern